Efficacy of Liposomal Amphotericin B in Treatment of Systemic Murine Fusariosis
AUTOR(ES)
Ortoneda, Montserrat
FONTE
American Society for Microbiology
RESUMO
We have compared the activities of liposomal amphotericin B (LAMB) at 3, 5, 10, and 20 mg/kg/day and amphotericin B deoxycholate (AMB) at 1.5 and 2.5 mg/kg/day in a murine systemic infection by Fusarium verticillioides. Survival was improved by all treatments except AMB at 1.5 mg/kg/day. The tissue burden in liver was reduced by LAMB at all dosages and by AMB at 2.5 mg/kg/day. The two highest dosages of LAMB showed significant reductions in the spleen.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127282Documentos Relacionados
- Liposomal amphotericin B therapy of murine histoplasmosis.
- PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice.
- Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice.
- Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.
- Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.
